Do GLP-1 receptor agonists reduce worsening heart failure events and the composite of cardiovascular death or worsening heart failure in patients with heart failure and mildly reduced or preserved ejection fraction?
GLP-1 receptor agonists show promise in reducing worsening heart failure events and cardiovascular death in patients with HFmrEF/HFpEF, particularly those with obesity or diabetes.
GLP-1RAs reduce worsening HF events and the composite of CV death or worsening HF in HFpEF, particularly in patients with obesity or diabetes. These findings support their role as a promising therapy requiring further HFpEF-focused trials.
Waqas et al. (Sat,) studied this question.